Search results for "SARS"

showing 10 items of 1372 documents

Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic

2020

On March 11, 2020, the WHO has declared the coronavirus disease 2019 (COVID-19) a global pandemic. As the last few months have profoundly changed the delivery of health care in the world, we should recognize the effort of numerous comprehensive cancer centers to share experiences and knowledge to develop best practices to care for oncological patients during the COVID-19 pandemic. Patients as well as physicians must be aware of all these constraints and profound social, personal, and medical challenges posed by the tackling of this deadly disease in everyday life in order to adjust to such a completely novel scenario. This review will discuss facing the challenges and the current approaches…

0301 basic medicineCancer ResearchCoronavirus disease 2019 (COVID-19)Best practiceDiseasechemotherapylcsh:RC254-28203 medical and health sciences0302 clinical medicineNursingPolitical scienceHealth carePandemicmedicinecancersevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Everyday lifebusiness.industrypandemicPerspective (graphical)Cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisPerspectivecoronavirus disease 2019 (COVID-19)businessFrontiers in Oncology
researchProduct

Cancer therapy and treatments during COVID-19 era

2020

The COVID-19 pandemic has put a serious strain on health treatments as well at the economies of many nations. Unfortunately, there is not currently available vaccine for SARS-Cov-2/COVID-19. Various types of patients have delayed treatment or even routine check-ups and we are adapting to a virtual world. In many cases, surgeries are delayed unless they are essential. This is also true with regards to cancer treatments and screening. Interestingly, some existing drugs and nutraceuticals have been screened for their effects on COVID-19. Certain FDA approved drugs, vitamin, natural products and trace minerals may be repurposed to treat or improve the prevention of COVID-19 infections and disea…

0301 basic medicineCancer ResearchDiseaseComorbidityAntineoplastic Agent0302 clinical medicineRepurposing approved drugNeoplasmsPandemicMedicineViralCancerNatural productsVitaminsSpike GlycoproteinHost-Pathogen InteractionDrug repositioning030220 oncology & carcinogenesisHost-Pathogen InteractionsSpike Glycoprotein CoronavirusMolecular MedicineNutraceuticalAngiotensin-Converting Enzyme 2NutraceuticalsCoronavirus InfectionsHumanHydroxychloroquineSignal Transductionmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAntineoplastic AgentsPeptidyl-Dipeptidase AAntiviral AgentsNatural productVitaminArticle03 medical and health sciencesBetacoronavirusGeneticsHumansIntensive care medicineMolecular BiologyPandemicsTrace ElementAntiviral AgentBetacoronaviruCoronavirus Infectionbusiness.industrySARS-CoV-2CanceRepurposing approved drugsDrug RepositioningrNatural productsCancerCOVID-19Pneumoniamedicine.diseaseComorbidityReview articleTrace ElementsCoronavirus030104 developmental biologyGene Expression RegulationSettore BIO/14 - FarmacologiaNeoplasmbusinessSpike Glycoprotein Coronaviru
researchProduct

More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study

2021

BackgroundThe aim of the study was to compare coronavirus disease 2019 (COVID-19) severity presentation between oncologic and non-oncologic patients and to evaluate the impact of cancer type and stage on COVID-19 course.MethodsWe performed a multicentre, retrospective study involving 13 COVID-19 Units in Campania region from February to May 2020. We defined as severe COVID-19 presentation the cases that required mechanical ventilation and/or admission to Intensive Care Units (ICU) and/or in case of death.ResultsWe enrolled 371 COVID-19 patients, of whom 34 (9.2%) had a history or a diagnosis of cancer (24 solid, 6 onco-hematological). Oncologic patients were older (p<0.001), had more…

0301 basic medicineCancer Researchmedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentoncologic patientseverity diseaseactive cancerMalignancy03 medical and health sciences0302 clinical medicineIntensive careInternal medicinemedicineStage (cooking)RC254-282Original ResearchMechanical ventilationSARS-CoV-2business.industryCOVID-19Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancerRetrospective cohort studymedicine.diseaseoncologic patients030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessCohort studyFrontiers in Oncology
researchProduct

COVID-19: viral–host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection

2020

AbstractBackgroundEpidemiological, virological and pathogenetic characteristics of SARS-CoV-2 infection are under evaluation. A better understanding of the pathophysiology associated with COVID-19 is crucial to improve treatment modalities and to develop effective prevention strategies. Transcriptomic and proteomic data on the host response against SARS-CoV-2 still have anecdotic character; currently available data from other coronavirus infections are therefore a key source of information.MethodsWe investigated selected molecular aspects of three human coronavirus (HCoV) infections, namely SARS-CoV, MERS-CoV and HCoV-229E, through a network based-approach. A functional analysis of HCoV-hos…

0301 basic medicineChemokinevirusesPneumonia ViralGene regulatory networklcsh:MedicineComputational biologyVirus-host interactomemedicine.disease_causeModels BiologicalInteractomeGeneral Biochemistry Genetics and Molecular BiologyTranscriptomePathogenesis03 medical and health sciencesBetacoronavirus0302 clinical medicineViral Envelope ProteinsProtein Interaction MappingmedicineCoronavirus infectionHumansGene Regulatory NetworksPandemicsGeneCoronavirusVirus–host interactomeMembrane GlycoproteinsInnate immune systembiologySARS-CoV-2Researchlcsh:RCOVID-19virus diseasesGeneral Medicinebiochemical phenomena metabolism and nutritionVirus–host interactome ; COVID-19 ; Coronavirus infection ; Spike glycoproteinPhenotyperespiratory tract diseasescoronavirus infection; spike glycoprotein; virus-host interactome030104 developmental biologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisHost-Pathogen Interactionsbiology.proteinSpike glycoproteinCoronavirus InfectionsSignal TransductionJournal of Translational Medicine
researchProduct

Molecular basis of SARS-CoV-2 infection and rational design of potential antiviral agents: Modeling and simulation approaches

2020

International audience; The emergence in late 2019 of the coronavirus SARS-CoV-2 has resulted in the breakthrough of the COVID-19 pandemic that is presently affecting a growing number of countries. The development of the pandemic has also prompted an unprecedented effort of the scientific community to understand the molecular bases of the virus infection and to propose rational drug design strategies able to alleviate the serious COVID-19 morbidity. In this context, a strong synergy between the structural biophysics and molecular modeling and simulation communities has emerged, resolving at the atomistic level the crucial protein apparatus of the virus and revealing the dynamic aspects of k…

0301 basic medicineComputer sciencedrug designIn silicoPneumonia Viralmembrane fusioncoronavirusReviewsDrug designComputational biologyMolecular Dynamics SimulationViral Nonstructural Proteinsmedicine.disease_causespike proteinAntiviral AgentsMolecular Docking SimulationBiochemistry[SPI.AUTO]Engineering Sciences [physics]/AutomaticModeling and simulationBetacoronavirus03 medical and health sciencesPandemicmedicineHumansstructural biophysicsPandemicsCoronavirus030102 biochemistry & molecular biologySARS-CoV-2free-energy methodsmolecular modelingRational designCOVID-19General ChemistryVirus InternalizationSARS unique domainmolecular dynamics3. Good healthMolecular Docking Simulation030104 developmental biologyDocking (molecular)Settore CHIM/03 - Chimica Generale E InorganicaSpike Glycoprotein CoronavirusdockingproteasesCoronavirus Infections
researchProduct

Attitudes and beliefs on influenza vaccination during the covid-19 pandemic: Results from a representative italian survey

2020

The last 2019/20 northern hemisphere influenza season overlapped with the first wave of coronavirus disease 2019 (COVID-19) pandemic. Italy was the first western country where severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread to a significant extent. In this representative cross-sectional survey, we aimed to describe some opinions and attitudes of the Italian general population towards both influenza vaccination and the COVID-19 pandemic, and to identify potential modifiers of the decision-making process regarding the uptake of the 2020/21 influenza vaccine. A total of 2543 responses were analyzed. Although most (74.8%) participants valued influenza vaccination positively …

0301 basic medicineCoronavirus disease 2019 (COVID-19)Influenza vaccineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyPopulationlcsh:MedicineInfluenza seasonArticleOddsSurvey.03 medical and health sciences0302 clinical medicinevaccineDrug DiscoveryPandemicMedicinePharmacology (medical)030212 general & internal medicineeducationSurveySettore MED/42 - IGIENE GENERALE E APPLICATAPharmacologyeducation.field_of_studyattitudesbusiness.industrylcsh:Rvirus diseasesCOVID-19InfluenzaVaccination030104 developmental biologyInfectious Diseasesinfluenza; COVID-19; vaccine; survey; vaccine hesitancy; attitudes; ItalyAttitudeItalyvaccine hesitancybusinessDemography
researchProduct

In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors

2020

Coronavirus Disease 2019 (COVID-19) is an infectious illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), originally identified in Wuhan, China (December 2019) and has since expanded into a pandemic. Here, we investigate metabolites present in several common spices as possible inhibitors of COVID-19. Specifically, 32 compounds isolated from 14 cooking seasonings were examined as inhibitors for SARS-CoV-2 main protease (Mpro), which is required for viral multiplication. Using a drug discovery approach to identify possible antiviral leads, in silico molecular docking studies were performed. Docking calculations revealed a high potency of salvianolic acid A and curcu…

0301 basic medicineCurcuminIn silicomedicine.medical_treatmentPneumonia ViralHealth InformaticsMolecular dynamicsMolecular Dynamics SimulationViral Nonstructural ProteinsArticleSARS-CoV-2 main proteaseBetacoronavirus03 medical and health scienceschemistry.chemical_compoundCaffeic Acids0302 clinical medicineDrug DiscoverymedicineHumansProtease InhibitorsSpicesPandemicsCoronavirus 3C Proteaseschemistry.chemical_classificationNatural productProteaseSARS-CoV-2Secondary metabolitesCOVID-19LopinavirAmino acidComputer Science ApplicationsMolecular Docking SimulationCysteine Endopeptidases030104 developmental biologyEnzymechemistryBiochemistryDocking (molecular)Molecular dockingLactatesCurcuminThermodynamicsCoronavirus Infections030217 neurology & neurosurgerymedicine.drugComputers in Biology and Medicine
researchProduct

The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19).

2021

Rationale: The pandemic caused by the novel coronavirus SARS-CoV-2 is advancing rapidly. In particular, the number of severe courses of the disease is still dramatically high. An efficient drug therapy that helps to improve significantly the fatal combination of damages in the airway epithelia, in the extensive pulmonary microvascularization and finally multiorgan failure, is missing. The physiological, inorganic polymer, polyphosphate (polyP) is a molecule which could prevent the initial phase of the virus life cycle, the attachment of the virus to the target cells, and improve the epithelial integrity as well as the mucus barrier. Results: Surprisingly, polyP matches perfectly with the ca…

0301 basic medicineDrug Evaluation PreclinicalMedicine (miscellaneous)Virus AttachmentRespiratory MucosaReviewmedicine.disease_causeAntiviral Agents03 medical and health sciencesMice0302 clinical medicinePolyphosphatesmedicineAnimalsHumansMode of actionReceptorPharmacology Toxicology and Pharmaceutics (miscellaneous)PandemicsMUC1Coronaviruschemistry.chemical_classificationChemistrySARS-CoV-2MucinMucinsCOVID-19Epithelial CellspolyphosphateMucusdigestive system diseasesCell biologyCOVID-19 Drug TreatmentDisease Models Animal030104 developmental biology030220 oncology & carcinogenesisAlkaline phosphataseNanoparticlesGlycoproteinviral receptor-binding domainTheranostics
researchProduct

SARS-CoV-2 and COVID-19: A genetic, epidemiological, and evolutionary perspective

2020

In less than five months, COVID-19 has spread from a small focus in Wuhan, China, to more than 5 million people in almost every country in the world, dominating the concern of most governments and public health systems. The social and political distresses caused by this epidemic will certainly impact our world for a long time to come. Here, we synthesize lessons from a range of scientific perspectives rooted in epidemiology, virology, genetics, ecology and evolutionary biology so as to provide perspective on how this pandemic started, how it is developing, and how best we can stop it.

0301 basic medicineEconomic growth[SDV]Life Sciences [q-bio]Gene ExpressionSeverity of Illness IndexDisease OutbreaksBiological CoevolutionChiropteraPandemicEpidemiologyPhylogenyComputingMilieux_MISCELLANEOUSEutheriaPhylodynamics3. Good healthEuropeInfectious DiseasesHost susceptibilityHost-Pathogen InteractionsSpike Glycoprotein CoronavirusAngiotensin-Converting Enzyme 2Coronavirus InfectionsMicrobiology (medical)medicine.medical_specialtyAsiaCoronavirus disease 2019 (COVID-19)Pneumonia Viral030106 microbiologyFILOGENIAPeptidyl-Dipeptidase ABiologyMicrobiologyArticleBetacoronavirus03 medical and health sciencesPoliticsGeneticsmedicineAnimalsHumansChinaPandemicsMolecular BiologyEcology Evolution Behavior and SystematicsSARS-CoV-2Public healthPerspective (graphical)COVID-19Immunity InnateCoronavirusImmune system030104 developmental biologyViral phylodynamicsNorth AmericaCoevolution
researchProduct

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

2021

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.

0301 basic medicineGenetically modified mouseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TransgenevirusesImmunologyefficacylcsh:Medicineimmunogenicitychallenge study03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicinePharmacologyMessenger RNAbiologybusiness.industrySARS-CoV-2Brief ReportImmunogenicitylcsh:RCOVID-19VirologyTiter030104 developmental biologyInfectious DiseasesmRNA vaccineImmunizationbiology.proteinAntibodybusinessVaccines
researchProduct